Double knockout CRISPR screen in cancer resistance to T cell cytotoxicity
Jonathan Joon-Young ParkiD, Adan Codina, Lupeng YeiD, Stanley Z. LamiD, Jianjian Guo, Paul R. ClarkiD, Xiaoyu ZhouiD, Lei PengiD, Sidi CheniD
Abstract
Immunotherapy has transformed cancer treatments; however, a large fraction of patients encounter resistance. Such resistance is mediated by complex factors, often involving interactions between multiple genes. Thus, it is crucially important to identify genetic interactions between genes that are significantly mutated in cancer patients and those involved in immune responses, ideally the ones that currently have chemical compounds for direct targeting. To systematically interrogate such genetic interactions that mediate cancer cells response to T cell killing, we designed an asymmetric CRISPR/Cas9 dual perturbation library targeting the matched combinations between significantly mutated tumor suppressors and immune resistance genes. We performed a combinatorial double knockout screen on 1,159 gene pairs and identified those where joint loss-of-function renders altered cellular response to T cell cytotoxicity. With individual double knockout constructs we validated these genetic interactions including Jak1-Trp53, Jak1-Kmt2d, and Ifngr1-Kmt2d. Interactions between significantly mutated tumor suppressors and potentially druggable immune resistance genes may offer insights on potential new concepts of how to target clinically relevant cancer mutations with currently available agents. This study also provides a technology platform and an asymmetric CRISPR double knockout library for interrogating genetic interactions between cancer mutations and immune resistance pathways under various settings.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 16
- FWCI
- 1.36
- Field percentile
- top 17%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen specific tumor cell killing by cytotoxic T cells
A.-K. Mattes, M. Puig Gamez, … L. K. Swee·bioRxiv·Aug 26, 2022
- Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy
R. J. Kishton, S. J. Patel, … N. P. Restifo·bioRxiv·Nov 18, 2019
- CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance
Alex Watterson, Gabriele Picco, … Matthew A. Coelho·Cell Reports MedicinePeer-reviewed·Jan 1, 2026
- Intercellular CRISPR Screens Enhance the Discovery of Cancer Immunotherapy Targets
- Mapping kinase-dependent tumor immune adaptation with multiplexed single-cell CRISPR screens
Lingting Shi, Ross M. Giglio, … José L. McFaline‐Figueroa·bioRxiv·Feb 28, 2026
- Applying CRISPR-based genetic screens to identify drivers of tumor-cell sensitivity towards NK-cell attack
Klara Klein, Tim Wang, … Wilfredo F. Garcia-Beltran·bioRxiv·Jan 27, 2019